Pfizer- US Commercial Operations

Pfizer- US Commercial Operations
Share

Strong, durable responses seen against lung tumors and brain metastases across multiple lines of therapy Monday, October 16, 2017 - 7:00amEDTPfizer Inc. (NYSE:PFE) today announced full results from the Phase 2 clinical trial of the investigational, next-generation tyrosine kinase inhibitor lorlatinib that exhibited clinically meaningful activity...

First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK Builds on Bavencio's previous accelerated approvals in the US and recent approval in Switzerland Approval based on data from Javelin Merkel 200 study including durable tumor response rate and duration of...

Longest Ever Follow-up Reported for Patients with Advanced ALK-positive NSCLC Monday, September 11, 2017 - 7:00amEDTPfizer Inc. (NYSE:PFE) today announced final overall survival (OS) data from the PROFILE 1014 trial examining XALKORI® (crizotinib) in previously untreated patients with ALK-positive advanced non-small cell lung cancer(NSCLC). After...

Data from the REFLECTIONS B327-02 study demonstrates equivalence in objective response rate (ORR) for patients with HER2-positive metastatic breast cancer Marketing applications accepted for review by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) Sunday, September 10, 2017 - 3:15amEDTPfizer Inc. (NYSE:PFE)...

Only approved antibody-drug conjugate for newly diagnosed and relapsed or refractory CD33-positive acute myeloid leukemia Reintroduction of MYLOTARG supported by continued research by the AML community demonstrating favorable risk:benefit profile Friday, September 1, 2017 - 11:38amEDTPfizer Inc. (NYSE:PFE) today announced that the U.S. Food and...

Applications seek to expand approved use of BOSULIF into first- line treatment based on positive results from Phase 3 head-to-head trial Tuesday, August 29, 2017 - 7:00amEDTPfizer Inc. (NYSE:PFE) and Avillion LLP today announced that a supplemental New Drug Application (sNDA) for BOSULIF® (bosutinib) has been accepted for filing and granted...

Eliquis® (apixaban) associated with lower risk of stroke and lower rates of major bleeding compared to warfarin in U.S. Humana database analysis Tuesday, August 29, 2017 - 8:21amEDTBristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced findings from a real-world data analysis of the U.S. Humana database, in which...

Eliquis® (apixaban) Clinical Data Include Results from a Phase 4 Trial – EMANATE – to be Featured in Late-Breaking Science Sessions Analyses from the ACROPOLIS™ Global Real-World Data Program Provide Insight into the Anticoagulation of a Broad Range of NVAF Patients at Risk for Stroke Friday, August 18, 2017 - 6:59amEDTBristol-Myers Squibb Company...

Bristol-Myers Squibb and Pfizer to Highlight Commitment to Reducing the Risk of Stroke Caused by Non-Valvular Atrial Fibrillation (NVAF) and Treating Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE) at ESC Congress 2017 Eliquis® (apixaban) Clinical Data Include Results from a Phase 4 Trial – EMANATE – to be Featured in Late-Breaking Science...

BESPONSA is the first and only CD22-directed antibody-drug conjugate indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia Thursday, August 17, 2017 - 1:57pmEDTPfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BESPONSA® (inotuzumab...